---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005292"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2026-08-06T11:30:20+00:00"
generated_at: "2026-08-06T11:35:52.163555+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics Q2 net loss $25.2M; tovecimig ORR improves to 18.0% with p=0.0228

## Summary
- Net loss of $25.2M ($0.13/sh) vs $19.9M ($0.14/sh) in Q2 2025; R&D spend rose 19% to $19.6M.
- Cash and marketable securities $180M as of June 30, 2026; runway into 2028.
- Tovecimig Phase 2/3 ORR improved to 18.0% (20/111) with p=0.0228 vs paclitaxel 5.3%.
- FDA feedback on tovecimig data expected Q3 2026; BLA submission planned later this year.
- CTX-8371 cohort expansions enrolling; CTX-10726 Phase 1 dosed; CTX-471 Phase 2 starts Q3.

## SEC filing metadata
- accession: 0001171843-26-005292
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2026-08-06T11:30:20+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/0001171843-26-005292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/f8k_080526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005292
- JSON: https://secwatch.observer/filing/0001171843-26-005292.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.